Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
nivolumab
nivolumab
- Restricted Opdivo Qvantig--> Restricted to Outpatient Medical.
- Restricted Anti-Neoplastic Formulary
- Non-formulary
VIEW MORE Antineoplastic Agents
Last updated: Mar. 17, 2026
Opdivo: Indicated for resistant cases of melanoma and NSCLC, given IV every 2 weeks. Defer to outpatient setting if possible. Rare inpatient use expected.
Opdivo Qvantig: Restricted to oncologist use in the outpatient setting.
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Opdivo medication guide
Reviewed: 25 August 2015 (Opdivo), February 2026 (Opdivo Qvantig)
Nivolumab_hyaluronidase-nvhy (OPDIVO QVANTIG) Spotlight.pdf